Featured Research

from universities, journals, and other organizations

Second Generation Drug-eluting Stent System Challenges Current Gold Standard

Date:
March 26, 2007
Source:
American College of Cardiology
Summary:
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A recent study surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.

While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions and controversy surrounding the safety and efficacy of drug-eluting stents continue to dominate discussions and headlines. A study presented at the American College of Cardiology's Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience™V Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.

Although Xience™V EES has demonstrated favorable results in pilot studies, the SPIRIT-III trial is the first large trial to study the system directly against the leading drug-eluting stent. The trial was conducted at 65 United States sites and enrolled 1,002 patients with coronary lesions in up to two coronary arteries. Patients were randomized in a 2:1 ratio to stent implantation with either Xience™V or PES. Patient outcomes were evaluated using angiography (use of X-rays to study the blood vessels) and intravascular ultrasound (IVUS -- use of a tiny ultrasound probe inserted into the coronary arteries to measure plaque).

Nine months after being implanted, patients treated with the XIENCE V stent compared to PES had similar rates of target vessel failure (7.2% vs. 9.0% respectively), but a strong trend toward fewer ischemic-driven target lesion revascularization procedures (2.6% vs. 5.0%). The rates of death, MI and stent thrombosis were similar with both stents. As a result, there were fewer major adverse cardiac events (MACE) at nine months in patients treated with the XIENCE V stent compared to PES (4.6% vs. 8.1%). At eight month angiographic follow-up, the XIENCE-V stent also significantly decreased in-segment late loss (0.14 mm vs. 0.28 mm) and the follow-up diameter stenosis (18.8% vs. 22.8%), which resulted in a strong trend toward reduced binary restenosis (4.7% vs. 8.9%).

"Drug-eluting stents continue to evolve, with enhanced drugs, polymers and delivery systems that will result in improved outcomes for patients with coronary artery disease," said Gregg W. Stone. M.D., of Columbia University Medical Center and lead author of the study. "The SPIRIT III trial demonstrates that the XIENCE V stent decreases angiographic restenosis and improves overall freedom from adverse events at nine months after implantation compared to the previously most widely used drug-eluting stent."

Dr. Stone will present the results of the "Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience™V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease" Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular interventionalists sponsored by the American College of Cardiology in partnership with the Society for Cardiovascular Angiography and Interventions.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "Second Generation Drug-eluting Stent System Challenges Current Gold Standard." ScienceDaily. ScienceDaily, 26 March 2007. <www.sciencedaily.com/releases/2007/03/070324132911.htm>.
American College of Cardiology. (2007, March 26). Second Generation Drug-eluting Stent System Challenges Current Gold Standard. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2007/03/070324132911.htm
American College of Cardiology. "Second Generation Drug-eluting Stent System Challenges Current Gold Standard." ScienceDaily. www.sciencedaily.com/releases/2007/03/070324132911.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins